Insmed

Nasdaq: INSM · SEC EDGAR filings

Results on file1
Average 24h move+8.25%across 1 result with a complete 24h price
1 resultInsmed
Met endpoint

ARIKAYCE

Phase 3 n=425 Mycobacterium Infections, Nontuberculous

Insmed INSM

24h stock move +8.25%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.